Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
about
Amplification of adenine phosphoribosyltransferase suppresses the conditionally lethal growth and virulence phenotype of Leishmania donovani mutants lacking both hypoxanthine-guanine and xanthine phosphoribosyltransferases.Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovaniComparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamstersSpermidine synthase is required for virulence of Leishmania donovani.Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animalsAdenine aminohydrolase from Leishmania donovani: unique enzyme in parasite purine metabolismAdenylosuccinate synthetase and adenylosuccinate lyase deficiencies trigger growth and infectivity deficits in Leishmania donovani.Leishmania donovani ornithine decarboxylase is indispensable for parasite survival in the mammalian host.Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.MIXED FORMULATION OF CONVENTIONAL AND PEGYLATED MEGLUMINE ANTIMONIATE-CONTAINING LIPOSOMES REDUCES INFLAMMATORY PROCESS AND PARASITE BURDEN IN L. infantum INFECTED BALB/c MICE.
P2860
Q33897846-E56B1EF0-7C31-4741-9E20-594366AB8FD8Q33983674-9E8A2794-4C6D-4E67-B140-BBB8A262F816Q34141596-3A88FBC5-C402-4CAF-8A9D-C2C188A466BBQ35328673-C89844BB-7BE5-4D48-B4A3-1EB9BDA6BDEFQ35685280-3898A80E-3F65-4121-BF8D-7B68BDA5D74FQ35802063-477ED9CD-F440-4522-8A68-E629316E0869Q36724945-567C4E89-C9EA-4E49-9C55-32B88DF5FC7CQ37075493-9C267037-6B93-4BBA-B68F-534A131CEEF5Q38376759-EFEFC45E-4FDB-45E7-82CB-5C2EDCFCCC66Q38718391-6AE09CDB-AFA7-4C33-827C-3B8EA5F4B896Q39954346-A47BE905-A70D-47A4-9538-8E80702E427FQ39955167-3B540DBF-46AC-401B-8793-E955099BC617Q40085162-936CDF2D-CA1C-4331-AF74-85F70F8E23D7
P2860
Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Visceral leishmaniasis in the ...... formulations of amphotericin B
@nl
Visceral leishmaniasis in the ...... ormulations of amphotericin B.
@ast
Visceral leishmaniasis in the ...... ormulations of amphotericin B.
@en
type
label
Visceral leishmaniasis in the ...... formulations of amphotericin B
@nl
Visceral leishmaniasis in the ...... ormulations of amphotericin B.
@ast
Visceral leishmaniasis in the ...... ormulations of amphotericin B.
@en
prefLabel
Visceral leishmaniasis in the ...... formulations of amphotericin B
@nl
Visceral leishmaniasis in the ...... ormulations of amphotericin B.
@ast
Visceral leishmaniasis in the ...... ormulations of amphotericin B.
@en
P2093
P2860
P356
P1476
Visceral leishmaniasis in the ...... formulations of amphotericin B
@en
P2093
P2860
P304
P356
10.1128/AAC.42.10.2722
P407
P577
1998-10-01T00:00:00Z